Oxford Biomedica Plc · LSE:OXB

Oxford Biomedica — FY2014 Earnings Presentation

24 slides from Oxford Biomedica's earnings presentation, March 2015

  1. Slide 1: World-leading expertise in Gene and Cell Therapy

    World-leading expertise in Gene and Cell Therapy 2014 Preliminary Results – March 2015

  2. Slide 2: Forward-looking statements

    Forward-looking statements This Cohortpresentation does 2 Dose not constituteAdministration an offer to sell or 3amonths solicitation (UPDRS) of offers to(UPDRS) 6 months buy Ordinary Shares 1 year (UPDRS) (the 2 years (UPDRS) “Securities”). 1, n=3 Although 1x reasonable care has Original been taken

  3. Slide 3: Operational Highlights

    Operational Highlights IP, technology and manufacturing capability is validated by Novartis • Major new licensing and manufacturing contract signed with Novartis in October 2014 Cohort 2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) • Worth up to $90 million ov

  4. Slide 4: Financial Highlights

    Financial Highlights • Total revenues of £13.6 million (excluding grants) in 2014 (2013: £5.4 million) Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% • Total revenues include profit-generating revenu

  5. Slide 5: Oxford BioMedica's business model

    Oxford BioMedica’s business model Cohort2 Dose Administration OXB 3 months (UPDRS) 6 months (UPDRS) IP Ownership 1 year (UPDRS) 2 years (UPDRS) 1, n=3 Research 1x & Original Mean 27% Solutions Mean 30% Mean 29% Mean 20% Key IP makes OXB + + Development Max. up to 30% Max. up to 50% Max. up to 44% Ma

  6. Slide 6: Gene therapy & cell therapy

    Gene therapy & cell therapy • Treating disease by altering genes/DNA in patients cells Cohort Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) • 2 Most commonly used viral vectors - Lentivirus or Adeno-Associated virus (AAV) 1, n=3 1x Original Mean 27% Mean 30% Me

  7. Slide 7: Gene therapy & cell therapy

    Gene therapy & cell therapy In vivo Cohort2 Dose Administration 3 months (UPDRS) Ex vivo 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Max. up to 30% Max. up to 50% Max. up to 44% Max. up to 30% ProSavin (Parkinson’s disease) ® 2, n=3 2x Origi

  8. Slide 8: OXB's unique capabilities

    OXB’s unique capabilities Slide for large image Proprietary development portfolio Lentiviral vector advantages Cell/Vector Process over AAV engineering development • Larger therapeutic payloads Lentiviral vector dominant patent OXB • Lentiviral vectors can be estate & know-how Solutions Manufacturin

  9. Slide 9: Product Portfolio

    Product Portfolio © Oxford BioMedica 2011, all rights reserved 9

  10. Slide 10: Portfolio of pipeline assets (excluding those already out-licensed)

    Portfolio of pipeline assets (excluding those already out-licensed) Est. Product Indication Stage Next inflection Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) date 2 years (UPDRS) Lentiviral 1, n=3 vector 1x TECHNOLOGY Original Mean 27% Mean 30% Mean 29% Mean 20% Max.

  11. Slide 11: 5T4 technology products

    5T4 technology products TroVax® • Cancer therapies & immunotherapy market forecast to increase to $36.8 billion by 2019 1 • TroVax® targets 5T4, onco-foetal tumour antigen expressed on surface of majority of solid tumours, stimulating immune system to destroy cancerous cells • Clinical trials show s

  12. Slide 12: Licences to OXB's IP and products

    Licences to OXB’s IP and products Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) Estimated 1 year (UPDRS) Estimated 2 years (UPDRS) 1, n=3 Company 1x Products Original Mean 27% Terms Mean 30% launch Mean date29% Peak Mean Yr 20%Sales Max. up to 30% Max. up to 50% Max. up to 44% Max. u

  13. Slide 13: Novartis contract

    Novartis contract © Oxford BioMedica 2011, all rights reserved 13

  14. Slide 14: CTL019

    CTL019 • FDA Breakthrough Therapy designation • Cohort2 Designation Dose supports the advancement3 months Administration of CTL019 (UPDRS) to help 6 monthsaddress (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 the unmet1x need of patients with relapsed/refractory Original Mean 27% acute Meanlymphobla

  15. Slide 15: Novartis contracts (October 2014)

    Novartis contracts (October 2014) • Initial contract May 2013 – proved our capabilities Cohort 2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) •1, n=3October 2014 1x contracts include Original Mean 27% Mean 30% Mean 29% Mean 20% Max. up to 30% Max. up to 50% Ma

  16. Slide 16: Financial update

    Financial update © Oxford BioMedica 2011, all rights reserved 16

  17. Slide 17: 2014 financial highlights

    2014 financial highlights1 • Total revenues increased to £13.6m (2013 £5.4m) • Recurring profit generating revenues increased to £7.7m (2013 £2.6m) Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) • 1, n=3 Cash used1xin operations Original Mean 27% (before

  18. Slide 18: Revenues – 2014 vs 2013

    Revenues – 2014 vs 2013 £m Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 9 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Max. up to 30% Max. up to 50% Max. up to 44% Max. up to 30% 8 2, n=3 2x Original Mean 28% Mean 34% Mean 29% - Max. up to 53

  19. Slide 19: Cash flow

    Cash flow £ millions 2014 2013 Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) Operating loss 1, n=3 1x before interest Original and tax Mean 27% Mean 30% (10.6) Mean 29% Mean 20% (12.8) Max. up to 30% Max. up to 50% Max. up to 44% Max. up to 30% Non-cash

  20. Slide 20: Financial outlook for 2015

    Financial outlook for 2015 • Continuing to build revenues from OXB Solutions business • Deliver Novartis requirements Cohort 2 • StriveDose to secure contracts Administration with other companies 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Me

  21. Slide 21: Summary

    Summary © Oxford BioMedica 2011, all rights reserved 21

  22. Slide 22: Upcoming potential value driving news flow

    Upcoming potential value driving news flow Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% 2015 RetinoStat Phase I final data results expected, ready for Phase II and/orMax. ® Max. up to 30% Max. up t

  23. Slide 23: Summary & outlook

    Summary & outlook • OXB is a unique and sector-leading gene/cell therapy business • Three-pronged strategy: 1) pipeline, 2) IP revenues, 3) OXB Solutions Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) Mean 27% 30% • n=3 IP and technical 1, 1x capabilitie

  24. Slide 24: Contact us

    Contact us Oxford BioMedica Cohort2 Dose plc Administration John Dawson, 6 months (UPDRS) CEO 3 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, Windrush n=3 Court 1x Original Mean 27%Tim Watts, Mean 30% CFO Mean 29% Mean 20% Transport Way Max. up to 30% Max. up to 50% Max. up to 44% Max. up to 30%

Oxford BioMedica — FY2014 Earnings Presentation on 6ix